Compumedics Reports Record A$60.3m FY26 Revenue and Launches Five-Program Value Realisation Strategy

Anjali Anand

11 November 2026 12:32 PM AEDT

Compumedics Reports Record A$60.3m FY26 Revenue and Launches Five-Program Value Realisation Strategy

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Compumedics Limited (ASX:CMP) has reported record revenue of A$60.3 million for FY26, a return to net profit after tax of A$0.25 million, and disclosed a new five-program Value Realisation Program targeting partnership, licensing, co-development and strategic investment opportunities across its Somfit®, OrionMEG® and DWL® technology platforms.

Key Points

FY26 revenue reached A$60.3 million, up 18.5% on FY25, with EBITDA of A$5.4 million representing a 74% increase and a margin of 9%
Net profit after tax of A$0.25 million was recorded in FY26, compared with a loss of A$1.3 million in FY25
Operating cash inflow was A$6.6 million in FY26, compared with A$0.4 million in FY25
Five dedicated value realisation programs have been established, with one adviser appointed for the Somfit® US pharmacy and consumer program; two to three further adviser appointments are expected by the end of the March 2027 quarter
The first 50 units of the single-use Somfit® D home sleep test were shipped to US customers in November 2026

FY26 Financial Results

Compumedics disclosed audited FY26 results showing revenue of A$60.3 million, EBITDA of A$5.4 million and net profit after tax of A$0.25 million. Operating cash inflow was A$6.6 million. Recurring revenue, comprising SaaS, consumables and customer care, reached A$18.3 million, representing 30% of total group revenue. Somfit® and NEXUS 360® SaaS revenue grew 70% to A$10.2 million, accounting for 17% of group revenue. More than one million studies have been recorded on the platform, including 257,000 in FY26 alone, with Somfit® contributing more than 110,000 of those studies.

Five-Program Value Realisation Strategy

The company's board has established five dedicated programs to pursue partnership, licensing, co-development and strategic investment, each supported by specialist deal makers. The programs cover three Somfit® verticals — US pharmacy and consumer, pharmaceutical and CRO trials, and cardiology — alongside a DWL® TCD AI-robotics program and an OrionMEG® program. Syed Husain of Red Brook Advisors, a former Head of Corporate Development and M&A at a Fortune 5 US healthcare company and registered pharmacist with more than 30 years' experience, has been appointed adviser for the Somfit® US pharmacy and consumer program. The filing states no transaction has been agreed and there is no certainty any transaction will proceed.

Guidance Revision and FY27 Outlook

Compumedics disclosed that FY26 revenue of A$60.3 million fell short of its original guidance of above A$70 million and its revised guidance range of A$62 million to A$65 million. The company attributed the shortfall to MEG shipment delays caused by helium supply and pricing disruption, and a later-than-planned US release of Somfit® D. The filing states A$28.3 million of open orders entered FY27, including A$13.1 million of MEG. FY27 guidance was disclosed as unchanged: double-digit revenue growth, with EBITDA growing faster than revenue. The company also said it will guide one year ahead only and report milestones only when delivered.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.